On August 20, 2025, Sarepta Therapeutics entered into agreements to exchange $700 million in existing convertible notes for new notes, stock, and cash. This included 5,851,693 shares of common stock and $123.3 million cash, with the new notes maturing in 2030 and bearing an interest rate of 4.875%.